25 October 2024 in Infection Control & Hospital Epidemiology
Background: Universal masking within healthcare settings was adopted to combat the spread of coronavirus disease 2019 (COVID-19). In addition to mitigating the risk for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, it also had an added benefit of preventing the nosocomial transmission of other respiratory viral diseases.Objective: This study examines the impact of the masking intervention on nosocomial respiratory viral infections (RVI) in vulnerable sub-populations of people with cancer at a tertiary care hospital.Design: Interrupted time series analysis.Methods: We reviewed non-SARS-CoV-2 nosocomial RVI between January 1, 2017 and December 31, 2023 and compared its quarterly trends before (January 2017 to March 2020) and after (April 2020 to December 2023) the universal masking intervention was implemented.Results: Prior to the masking policy, there was no significant change in the quarterly rate of non-SARS-CoV-2 nosocomial RVI (baseline trend: P = 0.662). Crude infection rates decreased from 5.6% preintervention to 4.3% after the masking policy was implemented (P < 0.001). Quarterly trends continued to steadily decline post-intervention (β = −0.10, SE = 0.04, P < 0.007).Conclusions: Our results suggest that universal face masking is associated with reduced non-SARS-CoV-2 nosocomial RVI, providing further evidence to support the continued use of face masks in healthcare settings to protect the health of immunocompromised patients.
15 January 2025 in Clinical Infectious Diseases
Background: Urinary tract infections are prone to overdiagnosis, and reflex urine culture protocols offer a valuable opportunity for diagnostic stewardship in this arena. However, there is no recommended standard testing approach. Patients with cancer are often excluded from reflex urine culture protocols, especially if they are severely immunosuppressed or neutropenic. The aim of this study was to evaluate the performance characteristics of urine screening studies, including dipstick urinalysis for nitrite and leukocyte esterase and urine microscopy for white blood cell count, to detect significant pathogen growth. Methods: A retrospective study of 58 098 urine cultures with a paired dipstick urinalysis with or without urine microscopy was performed at Memorial Sloan Kettering Cancer Center in New York City, evaluating data from 1 January 2018 to 31 December 2020. A dipstick urinalysis was considered negative only if leukocyte esterase and nitrite were undetected. Results: A negative dipstick urinalysis had a negative predictive value of 98% for clinically significant bacteriuria in voided urine and 95% for catheterized urine. Notably, a negative urine dipstick test screen maintained a high negative predictive value among patients with neutropenia and in those with antibiotic exposure before testing. Finally, the presence of pyuria ≥10 white blood cells per high-power field on urine microscopy offered negligible incremental diagnostic benefit in samples with a negative dipstick urinalysis. Conclusions: Reflex urine culture protocols contingent upon a screening dipstick urinalysis are a safe and effective platform for diagnostic stewardship in patients with cancer including those with neutropenia.
29 November 2022 in Clinical Infectious Diseases
Sotrovimab is an anti-spike neutralization monoclonal antibody developed to reduce the risk of coronavirus disease 2019 (COVID-19) progression and advancement to hospitalization in high-risk patients. Currently, there is limited research describing the association of sotrovimab treatment in patients with hematologic malignancy and the predictive factors of hospitalization. We performed an observational study of 156 consecutive cancer patients who received sotrovimab at Memorial Sloan Kettering Cancer Center in New York City during the BA.1 Omicron surge. We evaluated the demographic, clinical, and laboratory characteristics of the patients who had subsequent COVID-19–related hospitalization(s) compared to those who did not. Among the 156 study patients, 17 (11%) were hospitalized, of whom 4 were readmitted for COVID-19–related complications; 3 deaths were attributed to COVID-19. Results from multivariable logistic regression show that significant factors associated with hospitalization include patients on anti-CD20 therapy (adjusted odds ratio [aOR], 5.59 [95% confidence interval {CI}, 1.73–18.12]; P = .004) and with relapse/refractory disease (aOR, 5.69 [95% CI, 1.69–19.16]; P = .005). Additionally, whole genome sequencing of severe acute respiratory syndrome coronavirus 2 detected high occurrences of mutations in the spike gene associated with treatment-related resistance longitudinal samples from 11 patients treated with sotrovimab. While sotrovimab is effective at reducing COVID-19 hospitalization and disease severity in patients with hematologic malignancy when administered early, patients who received anti-CD20 antibodies showed substantial morbidity. Due to the high potential for resistance mutation to sotrovimab and increased morbidity in patients on anti-CD20 therapy, combination treatment should be explored to determine whether it provides added benefits compared to monotherapy.
24 February 2026 in Clinical Infectious Diseases
MSMaria Isabel Sotelo-Alva
+23
Among 667 CAR-T recipients, the 2-year cumulative incidence of RSV was 7%, with 29% of diagnosed cases progressing to LRTI. Older age and lymphopenia were associated with severity. Most infections (74%) occurred beyond day +100 (median 8 months). No RSV-attributable deaths occurred. Clinical vigilance is warranted, especially during RSV season.
3 December 2024 in Infection Control & Hospital Epidemiology
Background: SARS-CoV-2 asymptomatic surveillance testing (AST) is a common strategy to minimize the risk of nosocomial infection in patients and healthcare personnel. In contrast to admission screening, post-admission AST was less widely adopted.Objective: This study describes the diagnostic yield of post-admission serial SARS-COV-2 testing in hospitalized patients at a large cancer center with mostly double-occupancy rooms.Design: Retrospective cohort study design. Post-admission SARS-CoV-2 tests were examined over a 18 month study period. Positive results were reviewed to determine true hospital-onset infections using a combination criteria of screening all sample cycle threshold (Ct) values >30, results of non-concordant repeat testing, and clinical symptoms.Results: Post-admission serial testing of 15,048 hospitalized patients during an 18-month study period at a tertiary care cancer center detected hospital-onset infection in 1.6% (n = 245 patients). Among all hospital-onset positive SARS-CoV-2 RNA tests, 13% were clinically false positive. Most true infections were mild to moderate in severity.Conclusions: In summary, post-admission serial testing in a high-risk setting is a low-yield strategy with several unfavorable effects and should no longer be routinely applied.
7 July 2026 in Antimicrobial Stewardship & Healthcare Epidemiology
Background: Multiplex gastrointestinal polymerase chain reaction (GI-PCR) tests of the stool for the evaluation of infectious diarrhea are prone to false-positive target detections. However, there is no recommended testing approach in immunocompromised cancer patients who are often excluded from diagnostic stewardship protocols. The aim of this study was to evaluate the performance characteristics of the BioFire® FilmArray® GI-PCR and assess whether the findings support a diagnostic stewardship approach to limit testing among hospitalized cancer patients. Methods: A retrospective study of 29,727 GI-PCR tests was performed at Memorial Sloan Kettering Cancer Center in New York City, evaluating data from February 1, 2020, to January 29, 2025. All tests sent from all locations and across all patient types were included in the study. Results: The overall GI-PCR positivity rate was greatest in the outpatient setting at 23.4% and dropped at 15.6% in the early stage of admission (hospital days 0–2) and 10.1% in the late stage of admission (hospital day 3 and beyond). Across all subgroups analyzed, norovirus and Enteropathogenic E. coli (EPEC) were the most frequently detected targets with all remaining targets detected at rates below 2%. The low pathogen detection rate was preserved among patients with neutropenia and recipients of recent cellular therapy. Conclusion: BioFire FilmArray GI panel has low utility in the inpatient setting including for severely immunosuppressed hosts. These observations identify a potential opportunity for diagnostic stewardship and suggest that commonly applied testing restrictions may warrant further evaluation in immunocompromised oncology populations.